Premium
Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early‐stage Parkinson's disease
Author(s) -
Pyle Angela,
Brennan Rebecca,
KurzawaAkanbi Marzena,
Yarnall Alison,
Thouin Anais,
Mollenhauer Brit,
Burn David,
Chinnery Patrick F.,
Hudson Gavin
Publication year - 2015
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.24515
Subject(s) - cerebrospinal fluid , biomarker , mitochondrial dna , neurodegeneration , parkinson's disease , disease , stage (stratigraphy) , medicine , pathology , biology , oncology , genetics , gene , paleontology
The identification of cell‐free circulating mitochondrial DNA (ccf‐mtDNA) in early‐stage Alzheimer's disease (AD) raised the possibility that the same neurodegenerative effect could be observed in Parkinson's disease (PD). Here, and for the first time, we investigated the role of ccf‐mtDNA in PD, identifying a significant reduction of ccf‐mtDNA in PD patient cerebrospinal fluid (CSF) when compared to controls. Our data demonstrates that CSF ccf‐mtDNA is not only a powerful biomarker for PD, but, given that the effect is also observed in AD, is likely a biomarker for neurodegeneration. Ann Neurol 2015;78:1000–1004